Article
The FDA has consolidated three existing areas within the Center for Drug Evaluation and Research to form the Office of Oncology Drug Products.
Level of service for vasectomy prompts coding confusion
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
FDA approves Expanded Access Program to provide alternative source of BCG
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
PSMA staging is linked with higher rates of ADT, ARPI utilization in prostate cancer
Belzutifan approved in EU for renal cell carcinoma